BridgeBio Oncology Therapeutics, Inc. (BBOT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has a cash flow conversion efficiency ratio of -0.096x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.92 Million) by net assets ($372.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BBOT days of operational coverage to measure how many days the company can operate on defensive assets alone.
BridgeBio Oncology Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
BridgeBio Oncology Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Rike Chemical
SHE:300214
|
0.022x |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
-0.205x |
|
Linkage Software Co Ltd
SHG:688588
|
0.037x |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
-0.002x |
|
Gladstone Commercial Corporation
NASDAQ:GOOD
|
0.109x |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
-0.014x |
|
Beijing StarNeto Technology Co Ltd
SHE:002829
|
-0.003x |
|
Jinneng Science&Tech Co Ltd
SHG:603113
|
-0.049x |
Annual Cash Flow Conversion Efficiency for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see BBOT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $411.10 Million | $-113.89 Million | -0.277x | -6745.05% |
| 2024-12-31 | $188.72 Million | $-763.82K | -0.004x | -100.00% |
| 2023-12-31 | $-63.57K | $-52.08 Million | 819.252x | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more